{"product_id":"abcam-ab134922","title":"Abcam, ab134922, Anti-DPD antibody [EPR8811]","description":"\u003cp\u003eSize: 100µL \/ 1mL\u003cbr\u003e\nRabbit Recombinant Monoclonal DPD antibody. Suitable for IHC-P, WB, ICC\/IF, Flow Cyt (Intra) and reacts with Human samples. Cited in 7 publications.\u003cbr\u003e\nKey facts\u003cbr\u003e\nHost species:Rabbit,\u003cbr\u003e\nClonality:Monoclonal,\u003cbr\u003e\nClone number:EPR8811,\u003cbr\u003e\nIsotype:IgG,\u003cbr\u003e\nCarrier free:No,\u003cbr\u003e\nReacts with:Human,\u003cbr\u003e\nApplications:Flow Cyt (Intra), ICC\/IF, WB, IHC-PSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,\u003cbr\u003e\nImmunogen:The exact immunogen used to generate this antibody is proprietary information.\u003c\/p\u003e\n\n\u003cp\u003eProduct details:\u003cbr\u003e\nSpecies reactivity\u003cbr\u003e\nMouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species.\u003cbr\u003e\nPlease\u003cbr\u003e\ncontact us\u003cbr\u003e\nfor more information.\u003cbr\u003e\nPatented technology\u003cbr\u003e\nOur RabMAb\u003cbr\u003e\ntechnology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to\u003cbr\u003e\nRabMAb® patents\u003cbr\u003e\nWhat are the advantages of a recombinant monoclonal antibody?\u003cbr\u003e\nThis product is a recombinant monoclonal antibody, which offers several advantages including:\u003cbr\u003e\n- High batch-to-batch consistency and reproducibility\u003cbr\u003e\n- Improved sensitivity and specificity\u003cbr\u003e\n- Long-term security of supply\u003cbr\u003e\n- Animal-free batch production\u003cbr\u003e\nFor more information, read more on\u003cbr\u003e\nrecombinant antibodies\u003c\/p\u003e\n\n\u003cp\u003eProperties and Storage Information:\u003cbr\u003e\nForm-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Preservative: 0.01% Sodium azideConstituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA, Shipped at conditions-Blue Ice, Appropriate short-term storage duration-1-2 weeks, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions--20°C, Aliquoting information-Upon delivery aliquot, Storage information-Avoid freeze \/ thaw cycle\u003c\/p\u003e\n\n\u003cp\u003eSupplementary Information:\u003cbr\u003e\nThis supplementary information is collated from multiple sources and compiled automatically.\u003cbr\u003e\nDPD also known as dihydropyrimidine dehydrogenase is an enzyme important for the breakdown of pyrimidines particularly uracil and thymine. The DPD protein has an important role in the initial step of pyrimidine catabolism. It catalyzes the NADPH-dependent reduction of these pyrimidines to dihydrouracil and dihydrothymine. It consists of 1025 amino acids giving it a mass of approximately 111 kDa. DPD is expressed in various tissues with significant expression in the liver and to a lesser extent in peripheral blood lymphocytes.\u003cbr\u003e\nBiological function summary\u003cbr\u003e\nDihydropyrimidine dehydrogenase impacts nucleotide metabolism which is significant for cellular replication and repair processes. DPD exists as part of a multi-enzyme complex that handles pyrimidine metabolism. It serves an important regulatory function by controlling the level of pyrimidines within cells. This regulation keeps the balance of free nucleotides which is critical for DNA synthesis and overall cellular homeostasis.\u003cbr\u003e\nPathways\u003cbr\u003e\nDPD holds an important position in pyrimidine metabolism pathways and the drug metabolism pathway specifically influencing fluoropyrimidine-based chemotherapeutic agents. Within the pyrimidine metabolic pathway DPD links to other enzymes that further breakdown pyrimidines into more basic compounds. In drug metabolism DPD plays a vital role by metabolizing drugs like 5-fluorouracil. Its activity affects how individuals process these medications linking it to enzymes like thymidylate synthase that share pathways in cancer treatment drug action.\u003cbr\u003e\nDPD deficiency relates to a genetic disorder that causes an excessive build-up of uracil and thymine leading to developmental disorders and neurological problems. Additionally abnormalities in DPD activity influence the efficacy and toxicity of fluorouracil chemotherapy in cancer treatments. DPD enzymatic activity when not properly regulated can lead to severe toxic reactions especially in relation to therapies reliant on enzymes such as thymidylate synthase emphasizing the critical interplay between these proteins in the management of fluoropyrimidine drug treatments.\u003c\/p\u003e","brand":"Abcam","offers":[{"title":"Default Title","offer_id":46855837974697,"sku":"ab134922","price":0.99,"currency_code":"USD","in_stock":true}],"url":"https:\/\/iright.com\/es\/products\/abcam-ab134922","provider":"Iright","version":"1.0","type":"link"}